Johns Hopkins University

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Neal Fedarko

Jeremy D Walston

Peter M Abadir

Marian F Young

Larry W Fisher

Alka Jain

The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.

Angiotensin receptor autoantibodies as biomarker for effected usage of angiotensin receptor blockers

The invention provides methods and compositions for exploiting the discovery that members of the small integrin-binding ligand, n-linked glycoproteins family termed SIBLINGS bind to complement Factor H, and moreover that SIBLINGS proteins, such as BSP, exist in relatively acidic forms. The methods provided can be used to detect SIBLINGS proteins in samples from subjects that are suspected of having tumors or abnormal bone turnover. The invention also provides methods of using SIBLINGS proteins to protect cells from complement mediated lysis. Finally, the discovery allows for the creation of specific binding agents that facilitate the detection of SIBLINGS proteins when they are associated with Factor H.

Complex formed by N-linked glycoproteins (SIBLINGS)and Factor H

Growing community of inventors

Columbia, MD, United States of America

Neal Fedarko